New obesity drug Survodutide shows dramatic weight loss and liver health benefits
A new obesity treatment called Survodutide has shown promising results in clinical trials. Developed by Boehringer Ingelheim and Zealand Pharma, the drug helps patients lose significant weight while also improving liver health. Regulators in the US and Europe have already fast-tracked its review due to its potential benefits. Survodutide works by activating two key hormones: GLP-1 and glucagon. This dual action helps break down fat in the liver while reducing appetite. Early tests focused on overweight and obese patients without diabetes, where some lost up to 19% of their body weight over 46 weeks. In Phase II trials, participants also saw reductions in waist size by up to 16 cm and lost as much as 19.5 kg. Blood pressure improvements were recorded too, with drops of 8.6 mmHg in systolic and 4.8 mmHg in diastolic readings. The drug’s effects extended beyond weight loss, showing benefits for liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASH). Notably, up to 65% of adults with moderate to advanced liver scarring (F2 and F3 fibrosis stages) saw improvements after treatment. The US Food and Drug Administration granted Survodutide fast-track status in 2021, while the European Medicines Agency allowed an accelerated assessment in 2023. Survodutide’s results suggest it could become a key option for obesity and related liver conditions. With regulatory support already in place, further trials will determine its long-term safety and effectiveness. The drug’s dual mechanism offers a new approach for patients struggling with weight and metabolic health issues.
Read also:
- India's Agriculture Minister Reviews Sector Progress Amid Heavy Rains, Crop Areas Up
- Cyprus, Kuwait Strengthen Strategic Partnership with Upcoming Ministerial Meeting
- Inspired & Paddy Power Extend Virtual Sports Partnership for UK & Ireland Retail
- South West & South East England: Check & Object to Lorry Operator Licensing Now
